259 related articles for article (PubMed ID: 16883119)
1. Pharmacokinetics and the most suitable regimen of panipenem/beta mipron in critically ill patients receiving continuous renal replacement therapy: a pilot study.
Hayakawa M; Ito Y; Fujita I; Iseki K; Gando S
ASAIO J; 2006; 52(4):398-403. PubMed ID: 16883119
[TBL] [Abstract][Full Text] [Related]
2. Cefepime and continuous renal replacement therapy (CRRT): in vitro permeability of two CRRT membranes and pharmacokinetics in four critically ill patients.
Isla A; Gascón AR; Maynar J; Arzuaga A; Toral D; Pedraz JL
Clin Ther; 2005 May; 27(5):599-608. PubMed ID: 15978309
[TBL] [Abstract][Full Text] [Related]
3. The administration of ciprofloxacin during continuous renal replacement therapy: pilot study.
Hayakawa M; Fujita I; Iseki K; Gando S
ASAIO J; 2009; 55(3):243-5. PubMed ID: 19318919
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltration.
Tegeder I; Neumann F; Bremer F; Brune K; Lötsch J; Geisslinger G
Clin Pharmacol Ther; 1999 Jan; 65(1):50-7. PubMed ID: 9951430
[TBL] [Abstract][Full Text] [Related]
5. Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration.
DelDot ME; Lipman J; Tett SE
Br J Clin Pharmacol; 2004 Sep; 58(3):259-68. PubMed ID: 15327585
[TBL] [Abstract][Full Text] [Related]
6. Drug dosing during continuous renal replacement therapy.
Churchwell MD; Mueller BA
Semin Dial; 2009; 22(2):185-8. PubMed ID: 19426426
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy.
Isla A; Rodríguez-Gascón A; Trocóniz IF; Bueno L; Solinís MA; Maynar J; Sánchez-Izquierdo JA; Pedraz JL
Clin Pharmacokinet; 2008; 47(3):173-80. PubMed ID: 18307371
[TBL] [Abstract][Full Text] [Related]
8. Continuous renal replacement therapy in critically ill patients.
Zobel G; Rödl S; Urlesberger B; Kuttnig-Haim M; Ring E
Kidney Int Suppl; 1998 May; 66():S169-73. PubMed ID: 9573597
[TBL] [Abstract][Full Text] [Related]
9. Principles of antibacterial dosing in continuous renal replacement therapy.
Choi G; Gomersall CD; Tian Q; Joynt GM; Freebairn R; Lipman J
Crit Care Med; 2009 Jul; 37(7):2268-82. PubMed ID: 19487930
[TBL] [Abstract][Full Text] [Related]
10. Acute renal failure in critically ill surgical patients: persistent lethality despite new modes of renal replacement therapy.
Eachempati SR; Wang JC; Hydo LJ; Shou J; Barie PS
J Trauma; 2007 Nov; 63(5):987-93. PubMed ID: 17993940
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of RIFLE classification on prognosis of critically ill patients with acute kidney injury treated with continuous renal replacement therapy.
Li WX; Chen HD; Wang XW; Zhao S; Chen XK; Zheng Y; Song Y
Chin Med J (Engl); 2009 May; 122(9):1020-5. PubMed ID: 19493435
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of moxifloxacin and levofloxacin in intensive care unit patients who have acute renal failure and undergo extended daily dialysis.
Czock D; Hüsig-Linde C; Langhoff A; Schöpke T; Hafer C; de Groot K; Swoboda S; Kuse E; Haller H; Fliser D; Keller F; Kielstein JT
Clin J Am Soc Nephrol; 2006 Nov; 1(6):1263-8. PubMed ID: 17699357
[TBL] [Abstract][Full Text] [Related]
13. [Continuous renal replacement therapies (CRRT) will remain the most widely adopted dialysis modality in the critically ill].
Morabito S; Pistolesi V; Cibelli L; Pierucci A
G Ital Nefrol; 2009; 26(1):13-21. PubMed ID: 19255959
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of meropenem in children receiving continuous renal replacement therapy: Validation of clinical trial simulations.
Nehus EJ; Mizuno T; Cox S; Goldstein SL; Vinks AA
J Clin Pharmacol; 2016 Mar; 56(3):291-7. PubMed ID: 26222329
[TBL] [Abstract][Full Text] [Related]
15. The impact of variation in renal replacement therapy settings on piperacillin, meropenem, and vancomycin drug clearance in the critically ill: an analysis of published literature and dosing regimens*.
Jamal JA; Udy AA; Lipman J; Roberts JA
Crit Care Med; 2014 Jul; 42(7):1640-50. PubMed ID: 24674926
[TBL] [Abstract][Full Text] [Related]
16. Doripenem population pharmacokinetics and dosing requirements for critically ill patients receiving continuous venovenous haemodiafiltration.
Roberts JA; Udy AA; Bulitta JB; Stuart J; Jarrett P; Starr T; Lassig-Smith M; Roberts NA; Dunlop R; Hayashi Y; Wallis SC; Lipman J
J Antimicrob Chemother; 2014 Sep; 69(9):2508-16. PubMed ID: 24879665
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic/pharmacodynamic analysis.
Asín-Prieto E; Rodríguez-Gascón A; Trocóniz IF; Soraluce A; Maynar J; Sánchez-Izquierdo JÁ; Isla A
J Antimicrob Chemother; 2014 Jan; 69(1):180-9. PubMed ID: 23908259
[TBL] [Abstract][Full Text] [Related]
18. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy.
Trotman RL; Williamson JC; Shoemaker DM; Salzer WL
Clin Infect Dis; 2005 Oct; 41(8):1159-66. PubMed ID: 16163635
[TBL] [Abstract][Full Text] [Related]
19. Is regional citrate superior to systemic heparin anticoagulation for continuous renal replacement therapy? A prospective observational study in an adult regional critical care system.
Bagshaw SM; Laupland KB; Boiteau PJ; Godinez-Luna T
J Crit Care; 2005 Jun; 20(2):155-61. PubMed ID: 16139156
[TBL] [Abstract][Full Text] [Related]
20. The 90-day mortality and the subsequent renal recovery in critically ill surgical patients requiring acute renal replacement therapy.
Lin YF; Ko WJ; Chu TS; Chen YS; Wu VC; Chen YM; Wu MS; Chen YW; Tsai CW; Shiao CC; Li WY; Hu FC; Tsai PR; Tsai TJ; Wu KD;
Am J Surg; 2009 Sep; 198(3):325-32. PubMed ID: 19716882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
